The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials
Open accessAbstract
OBJECTIVE: To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile. DESIGN: Meta-analysis of four randomised controlled trials of aspirin for primary prevention. The benefit and harm from aspirin treatment were examined to determine: (1) the cardiovascular and coronary risk threshold at which benefit in prevention of myocardial infarction exceeds harm from significant bleeding; and (2) the absolute benefit expressed as number needed to treat (NNT) for aspirin net of cerebral haemorrhage and other bleeding complications at different levels of coronary risk. MAIN OUTCOME MEASURES: Benefit from aspirin, expressed as reduction in cardiovascular events, myocardial infarctions, strokes, and total mortality; harm caused by aspirin in relation to significant bleeds and major haemorrhages. RESULTS: Aspirin for primary prevention significantly reduced all cardiovascular events by 15% (95% confidence interval (CI) 6% to 22%) and myocardial infarctions by 30% (95% CI 21% to 38%), and non-significantly reduced all deaths by 6% (95% CI −4% to 15%). Aspirin non-significantly increased strokes by 6% (95% CI −24% to 9%) and significantly increased bleeding complications by 69% (95% CI 38% to 107%). The risk of major bleeding balanced the reduction in cardiovascular events when cardiovascular event risk was 0.22%/year. The upper 95% CI for this estimate suggests that harm from aspirin is unlikely to outweigh benefit provided the cardiovascular event risk is 0.8%/year, equivalent to a coronary risk of 0.6%/year. At coronary event risk 1.5%/year, the five year NNT was 44 to prevent a myocardial infarction, and 77 to prevent a myocardial infarction net of any important bleeding complication. At coronary event risk 1%/year the NNT was 67 to prevent a myocardial infarction, and 182 to prevent a myocardial infarction net of important bleeding. CONCLUSIONS: Aspirin treatment for primary prevention is safe and worthwhile at coronary event risk ⩾ 1.5%/year; safe but of limited value at coronary risk 1%/year; and unsafe at coronary event risk 0.5%/year. Advice on aspirin for primary prevention requires formal accurate estimation of absolute coronary event risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Statistical Methods in Medical Research.
Armitage, P. (1972) · Biometrics · doi:10.2307/2556182 · Cited by 4,029
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Cardiovascular disease risk profiles
Anderson, K. M., Odell, P. M., Wilson, P. W. F., & Kannel, W. B. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90861-b · Cited by 2,163
Randomised trial of prophylactic daily aspirin in British male doctors
Peto, R., Gray, R., Collins, R., Wheatley, K., Hennekens, C., Jamrozik, K., Warlow, C., Hafner, B., Thompson, E., Norton, S., et al. (1988) · BMJ · doi:10.1136/bmj.296.6618.313 · Cited by 1,166
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938 · cited 1×
“In this analysis reduction in myocardial infarction was used as the main measure of benefit because this end point accounted for all the benefit (see Results). Assuming relative risk reduction to be constant (as above) and using the combined odds ratio for all trials, the absolute reduction in myocardial infarction an…”
MethodInfluentialProphylactic aspirin and risk of peptic ulcer bleeding
Weil, J., Colin-Jones, D., Langman, M., Lawson, D., Logan, R., Murphy, M., Rawlins, M., Vessey, M., & Wainwright, P. (1995) · BMJ · doi:10.1136/bmj.310.6983.827 · Cited by 568
Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials
He, J., Whelton, P. K., Vu, B., & Klag, M. J. (1998) · JAMA · doi:10.1001/jama.280.22.1930 · Cited by 521
Hennekens, C. H., Dyken, M. L., & Fuster, V. (1997) · Circulation · doi:10.1161/01.cir.96.8.2751 · Cited by 435
Kelly, J. P., Kaufman, D. W., Jurgelon, J. M., Sheehan, J., Koff, R. S., & Shapiro, S. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01254-8 · Cited by 418
British Hypertension Society guidelines for hypertension management 1999: summary
Ramsay, L. E., Williams, B., Johnston, G. D., MacGregor, G. A., Poston, L., Potter, J. F., Poulter, N. R., & Russell, G. (1999) · BMJ · doi:10.1136/bmj.319.7210.630 · Cited by 373
Self-citationGrover, S. A. (1995) · JAMA · doi:10.1001/jama.274.10.801 · Cited by 219
Grover, S. A., Lowensteyn, I., Esrey, K. L., Steinert, Y., Joseph, L., & Abrahamowicz, M. (1995) · BMJ · doi:10.1136/bmj.310.6985.975 · Cited by 181
Wallis, E. J. (2000) · BMJ · doi:10.1136/bmj.320.7236.671 · Cited by 179
Self-citationMeade, T. W., & Brennan, P. J. (2000) · BMJ · doi:10.1136/bmj.321.7252.13 · Cited by 117
Kjeldsen, S. E., Kolloch, R. E., Leonetti, G., Malliond, J.-M., Zanchetti, A., Elmfeldt, D., Warnold, I., & Hansson, L. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018050-00017 · Cited by 116
Haq, I. U. (1999) · QJM · doi:10.1093/qjmed/92.7.379 · Cited by 47
Large trials with simple protocols: Indications and contraindications
Lubsen, J. C., & Tijssen, J. G. P. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90054-8 · Cited by 45
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Metadata
- Authors
- Sanmuganathan, P. S., Ghahramani, P., Jackson, P. R., Wallis, E. J., & Ramsay, L. E.
- Venue
- Heart
- Publisher
- BMJ
- Published
- 2001-03-01
- Volume
- 85
- Issue
- 3
- Pages
- 265-271
- ISSN
- 1355-6037 (ISSN-L)
- 1468-201X
- OpenAlex
- W2136486607
- Cited by
- 410
- References
- 20
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.